NICE says yes to Roche's MabThera for relapsed or refractory CLL
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for health and Clinical Excellence, looks poised to recommend Roche's anti-CD20 drug MabThera (rituximab) for treating certain patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).